vs
Bridgewater Bancshares Inc（BWB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Bridgewater Bancshares Inc的季度营收约是REGENXBIO Inc.的1.5倍（$46.2M vs $30.3M），Bridgewater Bancshares Inc净利率更高（37.7% vs -221.3%，领先259.0%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 31.4%）
布里奇沃特银行控股公司是总部位于美国明尼苏达州的区域性银行控股企业，主要为当地中小企业、个人消费者及商业客户提供商业贷款、存款产品、住房抵押贷款、个人银行等全方位商业与零售银行服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BWB vs RGNX — 直观对比
营收规模更大
BWB
是对方的1.5倍
$30.3M
净利率更高
BWB
高出259.0%
-221.3%
两年增速更快
RGNX
近两年复合增速
31.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $46.2M | $30.3M |
| 净利润 | $17.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 37.7% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 80.7% | -31.2% |
| 每股收益（稀释后） | $0.58 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BWBRGNX
| Q1 26 | $46.2M | — | ||
| Q4 25 | $38.8M | $30.3M | ||
| Q3 25 | $36.2M | $29.7M | ||
| Q2 25 | $36.1M | $21.4M | ||
| Q1 25 | $32.3M | $89.0M | ||
| Q4 24 | $29.5M | $21.2M | ||
| Q3 24 | $27.1M | $24.2M | ||
| Q2 24 | $26.8M | $22.3M |
净利润BWBRGNX
| Q1 26 | $17.4M | — | ||
| Q4 25 | $13.3M | $-67.1M | ||
| Q3 25 | $11.6M | $-61.9M | ||
| Q2 25 | $11.5M | $-70.9M | ||
| Q1 25 | $9.6M | $6.1M | ||
| Q4 24 | $8.2M | $-51.2M | ||
| Q3 24 | $8.7M | $-59.6M | ||
| Q2 24 | $8.1M | $-53.0M |
毛利率BWBRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率BWBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 44.2% | -190.0% | ||
| Q3 25 | 41.8% | -176.3% | ||
| Q2 25 | 42.0% | -296.3% | ||
| Q1 25 | 39.2% | 13.6% | ||
| Q4 24 | 35.6% | -242.1% | ||
| Q3 24 | 41.9% | -256.6% | ||
| Q2 24 | 39.7% | -251.3% |
净利率BWBRGNX
| Q1 26 | 37.7% | — | ||
| Q4 25 | 34.3% | -221.3% | ||
| Q3 25 | 32.1% | -208.3% | ||
| Q2 25 | 31.9% | -331.8% | ||
| Q1 25 | 29.8% | 6.8% | ||
| Q4 24 | 27.8% | -241.3% | ||
| Q3 24 | 32.0% | -246.3% | ||
| Q2 24 | 30.3% | -237.7% |
每股收益（稀释后）BWBRGNX
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.42 | $-1.30 | ||
| Q3 25 | $0.38 | $-1.20 | ||
| Q2 25 | $0.38 | $-1.38 | ||
| Q1 25 | $0.31 | $0.12 | ||
| Q4 24 | $0.26 | $-0.99 | ||
| Q3 24 | $0.27 | $-1.17 | ||
| Q2 24 | $0.26 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $528.4M | $102.7M |
| 总资产 | $5.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BWBRGNX
| Q1 26 | $222.2M | — | ||
| Q4 25 | $123.5M | $230.1M | ||
| Q3 25 | $131.8M | $274.2M | ||
| Q2 25 | $217.5M | $323.3M | ||
| Q1 25 | $166.2M | $267.9M | ||
| Q4 24 | $229.8M | $234.7M | ||
| Q3 24 | $191.9M | $255.5M | ||
| Q2 24 | $134.1M | $290.4M |
股东权益BWBRGNX
| Q1 26 | $528.4M | — | ||
| Q4 25 | $517.1M | $102.7M | ||
| Q3 25 | $497.5M | $161.5M | ||
| Q2 25 | $476.3M | $213.7M | ||
| Q1 25 | $469.0M | $274.2M | ||
| Q4 24 | $457.9M | $259.7M | ||
| Q3 24 | $452.2M | $301.4M | ||
| Q2 24 | $439.2M | $348.3M |
总资产BWBRGNX
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.4B | $453.0M | ||
| Q3 25 | $5.4B | $525.2M | ||
| Q2 25 | $5.3B | $581.0M | ||
| Q1 25 | $5.1B | $490.9M | ||
| Q4 24 | $5.1B | $466.0M | ||
| Q3 24 | $4.7B | $519.1M | ||
| Q2 24 | $4.7B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BWBRGNX
| Q1 26 | — | — | ||
| Q4 25 | $27.8M | $-52.3M | ||
| Q3 25 | $9.4M | $-56.0M | ||
| Q2 25 | $4.0M | $-49.3M | ||
| Q1 25 | $7.5M | $33.6M | ||
| Q4 24 | $46.4M | $-31.6M | ||
| Q3 24 | $-6.0M | $-40.5M | ||
| Q2 24 | $10.6M | $-45.5M |
自由现金流BWBRGNX
| Q1 26 | — | — | ||
| Q4 25 | $22.0M | $-52.8M | ||
| Q3 25 | $7.8M | $-56.5M | ||
| Q2 25 | $2.8M | $-49.7M | ||
| Q1 25 | $6.9M | $32.6M | ||
| Q4 24 | $42.3M | $-32.7M | ||
| Q3 24 | $-6.5M | $-40.9M | ||
| Q2 24 | $10.4M | $-46.0M |
自由现金流率BWBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 56.6% | -174.0% | ||
| Q3 25 | 21.5% | -189.9% | ||
| Q2 25 | 7.8% | -232.8% | ||
| Q1 25 | 21.5% | 36.6% | ||
| Q4 24 | 143.4% | -154.2% | ||
| Q3 24 | -23.8% | -168.9% | ||
| Q2 24 | 38.9% | -206.2% |
资本支出强度BWBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 15.1% | 1.7% | ||
| Q3 25 | 4.4% | 1.7% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 1.7% | 1.2% | ||
| Q4 24 | 13.8% | 5.1% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 0.7% | 2.1% |
现金转化率BWBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | — | ||
| Q3 25 | 0.81× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.77× | 5.53× | ||
| Q4 24 | 5.65× | — | ||
| Q3 24 | -0.69× | — | ||
| Q2 24 | 1.31× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BWB
| Net Interest Income | $36.6M | 79% |
| Noninterest Income | $9.6M | 21% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
